Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares

PALO ALTO, Calif., October 31, 2017 /PR Newswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the closing of its underwritten public offering of 2,132,961 shares of its common stock that included the exercise in full of the underwriter’s option to purchase up to 278,212 shares, at a price of $10.00 per share. The offering was made under the company’s effective shelf registration statement and resulted in net proceeds to the company of approximately $19.5 million, after underwriting discounts and commissions and estimated offering expenses.

BTIG, LLC. acted as sole book-running manager for this offering.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on June 17, 2016 and declared effective by the SEC on August 4, 2016. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. The prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may be obtained by contacting BTIG, LLC, at 825 Third Avenue, 6th Floor, New York, NY 10022, or by email at equitycapitalmarkets@btig.com, or by phone at 212-593-7555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Eiger BioPharmaceuticals, Inc.
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Eiger BioPharmaceuticals


Jim Welch
Eiger BioPharmaceuticals, Inc.
Phone: (650) 279-9845
Email: jwelch@eigerbio.com

PDF Icon

See More Press Releases